News & Updates

Show Multimedia Only

Novel MET kinase inhibitor counteracts TKI resistance in NSCLC

09 Dec 2022 by

Treatment with SCC244, a novel small molecule inhibitor of the enzyme MET kinase, appears to help overcome the resistance to tyrosine kinase inhibitors (TKI) mediated by MET amplification in nonsmall cell lung cancer (NSCLC), reports a new study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).

09 Dec 2022

Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC

09 Dec 2022

The addition of radiation therapy to chemotherapy may be more detrimental than beneficial in patients with resectable stage III nonsmall‐cell lung cancer (NSCLC), being associated with a heightened risk of severe cardiac events, as shown in a study.

09 Dec 2022

Progestin shows therapeutic potential in PR-positive endometrial cancer

08 Dec 2022

Progestin therapy appears to yield high response rates in advanced stage and recurrent endometrial cancer that is positive for progesterone receptor (PR) expression, while having low toxicity, according to a study.

08 Dec 2022

Veverimer does not delay CKD progression

07 Dec 2022 by

Treatment with once-daily veverimer did not delay chronic kidney disease (CKD) progression, according to the results of the phase III VALOR-CKD trial.

07 Dec 2022

Degarelix tied to BMD decrease in prostate cancer

07 Dec 2022

Treatment with degarelix results in a substantial reduction in bone mineral density (BMD) and an increase in bone turnover markers, reports a study.

07 Dec 2022

PCSK9 inhibitors safe, effective in Asian patients, but expensive to use

07 Dec 2022 by

PCSK9 inhibitors alirocumab and evolocumab are not only safe and well tolerated but also efficacious in Asian patients, results of a real-world study in Singapore have shown. However, about a third of patients stopped using these medications due to their high costs.

07 Dec 2022

DUET OLE supports long-term nephroprotection of sparsentan for FSGS patients

07 Dec 2022 by

Results from the open-label extension (OLE) period of the phase II DUET trial demonstrated the long-term nephroprotective potential and safety of sparsentan for individuals with focal segmental glomerulosclerosis (FSGS).

07 Dec 2022

First-line ablation averts AF progression

07 Dec 2022 by

Among patients with paroxysmal atrial fibrillation (AF), initial treatment with cryoballoon ablation reduced the incidence of persistent AF through 3 years of follow-up compared with antiarrhythmic drug (AAD) therapy, according to the PROGRESSIVE-AF* trial presented at AHA 2022.

07 Dec 2022

Erenumab works well in chronic migraine patients across Asia

06 Dec 2022 by

Erenumab proves to be effective at lowering the number of monthly migraine days in Asian patients with chronic migraine while having a favourable safety profile, according to the results of DRAGON study.

06 Dec 2022

Weekly somapacitan on par with daily growth hormone in children

06 Dec 2022 by

Weekly somapacitan is noninferior to daily growth hormone (GH) in terms of height velocity (HV), with comparable safety and mean insulin-like growth factor-1 standard deviation score (IGF-1 SDS) levels in treatment-naïve children with growth hormone deficiency (GHD), a study has shown.

06 Dec 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Novel MET kinase inhibitor counteracts TKI resistance in NSCLC

Add-on radiation therapy poses higher cardiovascular risk in stage III NSCLC

Progestin shows therapeutic potential in PR-positive endometrial cancer

Veverimer does not delay CKD progression

Degarelix tied to BMD decrease in prostate cancer

PCSK9 inhibitors safe, effective in Asian patients, but expensive to use

DUET OLE supports long-term nephroprotection of sparsentan for FSGS patients

First-line ablation averts AF progression

Erenumab works well in chronic migraine patients across Asia

Weekly somapacitan on par with daily growth hormone in children